Back to Search
Start Over
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
- Publication Year :
- 2020
-
Abstract
- AIMS: To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence of dyspnoea reported as adverse event (AE) that may lead to treatment non-adherence. METHODS AND RESULTS: This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the experimental strategy of 23-month ticagrelor monotherapy following 1-mon
Details
- Database :
- OAIster
- Notes :
- application/pdf, European heart journal. Cardiovascular pharmacotherapy vol. 6 no. 4, pp. 222-230, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1244879376
- Document Type :
- Electronic Resource
- Full Text :
- https://doi.org/10.1093.ehjcvp.pvz052